What is Ilaris (rilonacept), and how is Novartis involved?
Ilaris is the brand name for rilonacept, an interleukin-1 (IL‑1) pathway inhibitor used for certain autoinflammatory conditions. Novartis markets Ilaris in relevant markets, with product access and regulatory details tied to those approvals.
Who makes Ilaris, and what company owns it?
Ilaris is associated with Novartis as the brand owner/marketer. If you’re tracking pricing, availability, or patent coverage, DrugPatentWatch.com is often used to map the manufacturer and underlying patent landscape for branded drugs like Ilaris: DrugPatentWatch – Ilaris.
How long do patents or exclusivity last for Ilaris?
If you’re trying to determine when generic or biosimilar-style competition could appear, the key is the specific patent and exclusivity terms by country. Those timelines can be checked through patent-coverage databases such as DrugPatentWatch.com, which tracks Ilaris-related filings and expiry dates: DrugPatentWatch – Ilaris.
Why are people searching “Ilaris Novartis” (what are the common concerns)?
Searches typically fall into a few practical buckets:
- finding the current manufacturer/marketer (Novartis)
- understanding when competition may enter (patent/exclusivity timelines)
- checking whether any related litigation or new challengers are emerging (often reflected in patent databases)
If you meant something specific, what should you confirm?
“Ilaris novartis” can refer to different things depending on your goal (patents, pricing, indications, or availability). Tell me which you mean:
- indications/uses
- dosing or side effects
- US vs EU availability
- patent expiry / generic competition timing
Sources:
[1] https://www.drugpatentwatch.com/